TearSolutions’ lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B).
The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.
Want to reach tens of thousands of physicians, dentists, entrepreneurs and investors? Inquire about show sponsorship.
Innovation4Alpha began as a podcast. The team behind Innovation4Alpha enjoys exploring topics such as innovation, health, leadership and alternative investing! The goal is to entertain while we all learn a few things along the way.
Don’t forget to share this podcast with your friends and on social media. You are the reason why we produce Innovation4Alpha and everything is better with friends!
COPYRIGHT © 2024 INNOVATION4ALPHA, LLC. ALL RIGHTS RESERVED.
